30-day risks following CEA and CAS in trials that randomised >500 recently symptomatic patients into EVA-3S, SPACE, International Carotid Stenting Study (ICSS) and CREST8 9 11 18
| 30-day risks | EVA-3S8 | SPACE9 | ICSS11 | CREST*18 | ||||
| CEA (n=262) | CAS (n=261) | CEA (n=589) | CAS (n=607) | CEA (n=857) | CAS (n=853) | CEA (n=653) | CAS (n=668) | |
| Death | 1.2% | 0.8% | 0.9% | 1.0% | 0.8% | 2.3% | ||
| Any stroke | 3.5% | 9.2% | 6.2% | 7.2% | 4.1% | 7.7% | 3.2% | 5.5% |
| Death/any stroke | 3.9% | 9.6% | 6.5% | 7.4% | 4.7% | 8.5% | 3.2% | 6.0% |
| Death/disabling stroke | 1.5% | 3.4% | 3.8% | 5.1% | 3.2% | 4% | ||
| Death/stroke/MI | 5.2% | 8.5% | 5.4% | 6.7% | ||||
| Cranial nerve injury | 7.7% | 1.1% | 5.3% | 0.1% | 5.1% | 0.5% | ||
*Only includes symptomatic patients from CREST.
CAS, carotid artery stenting; CEA, carotid endarterectomy; CREST, Carotid Revascularisation versus Stenting Trial; EVA-3S, Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis; MI, myocardial infarction; SPACE, Stent-Protected Angioplasty versus Carotid Endarterectomy.